Market Overview

Rheumatoid Arthritis: Update Bulletin #3 -


The "Rheumatoid
Arthritis: Update Bulletin #3"
newsletter has been added to's

Business Questions

  • How do KOLs perceive Boehringer Ingelheim's adalimumab biosimilar,
  • With three adalimumab biosimilars now approved in Europe, what
    concerns do prescribers have with regard to multiple biosimilar
    versions becoming available?
  • How do KOLs view Sandoz's Rixathon, the second rituximab biosimilar to
    enter the RA space in Europe?
  • Celltrion is currently developing a subcutaneously administered
    infliximab biosimilar, but what need is there currently for a
    subcutaneous version of this product?
  • What concerns might prescribers have regarding Celltrion's
    subcutaneous infliximab biosimilar?

For more information about this newsletter visit

View Comments and Join the Discussion!